Disease Domain | Count |
---|---|
Nervous System Diseases | 3 |
Infectious Diseases | 2 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Chemical drugs | 1 |
Target |
Mechanism RAD52 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Orexin receptor antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism cccDNA inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Aug 2019 |
Sponsor / Collaborator [+1] |
Start Date01 Sep 2016 |
Sponsor / Collaborator |
Start Date01 Jul 2016 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
D-I03 ( RAD52 ) | Neoplasms More | Preclinical |
RTIOX-276 ( Orexin receptor ) | Cocaine-Related Disorders More | Preclinical |
GT-949 ( EAAT2 ) | Central Nervous System Diseases More | Discovery |
CCC-0346 ( cccDNA ) | Hepatitis B More | Discovery |
NA-014 ( EAAT2 ) | Central Nervous System Diseases More | Discovery |